Royal UNIBREW A/S
16.11.2026 14:27:54 CET | Globenewswire | Press release
Share buy-back program
Share buy-back program
COMPANY ANNOUNCEMENT NO 59/2026 - November 16, 2026
On August 17, 2026, Royal Unibrew announced a share buy-back program, cf. company announcement no. 44/2026.
The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of April 16, 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”).
The share buy-back program is expected to be realized in the period from August 18, 2026, to December 18, 2026. The total transaction value of the share buy-backs in the period will not exceed DKK 300m.
The following transactions have been made under the program:
| Number of Shares | Average purchase price DKK | Transaction value, DKK | |
| Accumulated, last announcement | 487,399 | 423.29 | 206,311,253 |
| November 9, 2026 | 7,000 | 452.08 | 3,164,582 |
| November 10, 2026 | 7,000 | 456.12 | 3,192,865 |
| November 11, 2026 | 6,500 | 453.17 | 2,945,628 |
| November 12, 2026 | 6,500 | 467.18 | 3,036,697 |
| November 13, 2026 | 6,700 | 471.32 | 3,157,817 |
| Total accumulated under the program | 521,099 | 425.66 | 221,808,842 |
With the transactions stated above Royal Unibrew owns a total of 2,303,687 shares, corresponding to 4.7% of the share capital. The total amount of shares in the company is 49,300,000, including treasury shares.
For further information please contact:
Flemming Ole Nielsen (Head of Investor Relations)
E-mail: Flemming.Nielsen@royalunibrew.com
Telephone: +45 25 41 68 04
Encl.
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S16.11.2026 14:24:18 CET | Press release
Novo Nordisk A/S - share repurchase programme
Bitget Limited16.11.2026 14:00:00 CET | Press release
Bitget Launches rToken Earn, Bringing Onchain Yield to Tokenized ETFs with Bitwise Set to Curate the Strategy
Teva Pharmaceutical Industries Ltd16.11.2026 14:00:00 CET | Press release
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
MacuMira Medical Devices Inc.16.11.2026 14:00:00 CET | Press release
MacuMira Receives CE Mark for Its Microcurrent Treatment for Dry AMD
ALK Abello16.11.2026 13:39:46 CET | Press release
ALK to present at the Jefferies Global Healthcare Conference in London
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom